 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia PR Newswire...

TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results PR Newswire EDINBURGH...

TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with...

TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials

TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements PR...

TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements

Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness...

Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

TC Biopharm files to sell 12.94M American Depositary Shares

TC BioPharm to Present at the LD Micro Main Event XVI TC BioPharm to Present at the LD Micro Main Event XVI PR Newswire EDINBURGH, Scotland, Sept. 27, 2023 EDINBURGH, Scotland, Sept. 27, 2023...

TC BioPharm to Present at the LD Micro Main Event XVI

TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference PR Newswire EDINBURGH, Scotland, Aug. 29, 2023 EDINBURGH, Scotland, Aug. 29, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC...

TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference

TC BioPharm Maintains Nasdaq Listing TC BioPharm Maintains Nasdaq Listing PR Newswire EDINBURGH, Scotland, July 31, 2023 Regains Compliance with Rule 5550(b)(2) EDINBURGH, Scotland, July 31, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ('TC BioPharm' or the 'Company&quot...

TC BioPharm Maintains Nasdaq Listing

Phoenix, Arizona--(Newsfile Corp. - July 6, 2023) - The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. (NASDAQ: TCBP) ("the Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of ...

TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company was founded by Michael Leek and Angela Scott in 2013 and is headquartered in Motherwell, the United Kingdom.

Watchers	5,180
52-Wk Low	$0.33
52-Wk High	$9.61

Market Cap	$2.44M
Volume (M)	1.06M
52-Wk High	$9.61
52-Wk Low	$0.33

TCBP TC BioPharm Holdings Ltd

About

Feed

News

Fundamentals